查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1800795

神經退化性疾病治療市場報告（按適應症、藥物類型、給藥途徑、配銷通路和地區）2025 年至 2033 年

Neurodegenerative Disease Treatment Market Report by Indication, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3個工作天內

價格

2024年全球神經退化性疾病治療市場規模達783億美元。展望未來， IMARC Group預計到2033年市場規模將達到1,185億美元，2025-2033年期間的成長率（CAGR）為4.48%。

神經退化性疾病是指一組導致中樞神經系統 (CNS) 或周邊神經系統 (PNS) 神經元結構和功能逐漸退化的腦部疾病。目前，已有多種藥物可用於減輕患者的身體或精神症狀，並改善其生活品質。此外，研究人員正致力於開發分子診斷技術，尤其是生物標記和成像光譜技術，以便在早期檢測和診斷神經退化性疾病並阻止其進展。

由於過度飲酒導致腫瘤和中風發生率不斷上升，再加上老年人口不斷成長，是增加神經退化性疾病風險的主要因素之一。這進一步加劇了對用於早期診斷神經退化性疾病（包括阿茲海默症、帕金森氏症、亨丁頓舞蹈症和肌萎縮側索硬化症）的分子診斷技術的需求。此外，研究人員正在將神經病理學方法與分子生物學技術相結合，以有效地了解這些疾病的分類。他們也正在開發針對不同類型神經退化性疾病的微創 (MI) 篩檢檢測。此外，許多國家的管理機構以及非政府組織 (NGO) 正在支持各種健康教育活動，以提高人們對神經退化性疾病風險因素的認知。其他因素，例如由於基礎設施改善和可支配收入增加而增加的醫療服務可近性，預計將在未來幾年推動市場的成長。

本報告回答的關鍵問題：

  • 全球神經退化性疾病治療市場迄今表現如何，未來幾年將如何表現？
  • COVID-19 對全球神經退化性疾病治療市場有何影響？
  • 主要的區域市場有哪些？
  • 根據指示，市場區隔如何？
  • 根據藥物類型，市場是如何分類的？
  • 根據行政路徑，市場如何分類？
  • 根據配銷通路，市場如何分類？
  • 該產業的價值鏈分為哪些階段？
  • 該行業的主要促進因素和挑戰是什麼？
  • 全球神經退化性疾病治療市場的結構是如何的？主要參與者是誰？
  • 產業競爭程度如何？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：全球神經退化性疾病治療市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依指標

  • 多發性硬化症
  • 帕金森氏症
  • 阿茲海默症
  • 脊髓性肌肉萎縮症（SMA）
  • 亨廷頓舞蹈症
  • 其他

第7章：市場區隔：依藥物類型

  • N-甲基-D-天門冬胺酸受體拮抗劑
  • 選擇性血清素再攝取抑制劑
  • 多巴胺抑制劑
  • 其他

第8章：市場區隔：依行政途徑

  • 口服
  • 注射劑
  • 其他

第9章：市場區隔：按配銷通路

  • 醫院藥房
  • 零售藥局
  • 其他

第10章：市場細分：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第 11 章：SWOT 分析

第 12 章：價值鏈分析

第 13 章：波特五力分析

第 14 章：價格分析

第 15 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Biogen
    • Boehringer Ingelheim International GmbH
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline Plc
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
    • UCB SA
Product Code: SR112025A3102

The global neurodegenerative disease treatment market size reached USD 78.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 118.5 Billion by 2033, exhibiting a growth rate (CAGR) of 4.48% during 2025-2033.

Neurodegenerative diseases refer to a group of brain disorders that lead to progressive degeneration of the structure and function of neurons in the central nervous system (CNS) or peripheral nervous system (PNS). Presently, several medications are available to reduce physical or mental symptoms and improve the quality of patients' life. Moreover, researchers are focusing on developing molecular diagnostics, especially biomarkers and imaging spectroscopy, to detect and diagnose neurodegenerative diseases at an early stage and prevent their progression.

The growing prevalence of tumors and stroke on account of excessive alcohol consumption, in confluence with the rising geriatric population, represents one of the major factors increasing the risk of developing neurodegenerative diseases. This is further escalating the need for molecular diagnostic techniques for early diagnosis of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Apart from this, researchers are combining neuropathological methods with molecular biology techniques to understand the classification of these diseases effectively. They are also developing minimally invasive (MI) screening tests for different types of neurodegenerative diseases. Furthermore, governing agencies of numerous countries, along with non-governmental organizations (NGOs), are supporting various health education campaigns to generate awareness about the risk factors of neurodegenerative diseases. Other factors, such as increasing access to healthcare facilities on account of improving infrastructure and inflating disposable incomes, are anticipated to drive the growth of the market in the coming years.

Key Market Segmentation:

Breakup by Indication:

  • Multiple Sclerosis
  • Parkinson's Disease
  • Alzheimer's Disease
  • Spinal Muscular Atrophy (SMA)
  • Huntington's Disease
  • Others

Breakup by Drug Type:

  • N-methyl-D-aspartate Receptor Antagonists
  • Selective Serotonin Reuptake Inhibitors
  • Dopamine Inhibitors
  • Others

Breakup by Route of Administration:

  • Oral
  • Injectable
  • Others

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Biogen, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd. and UCB S.A.

Key Questions Answered in This Report:

  • How has the global neurodegenerative disease treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global neurodegenerative disease treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the indication?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global neurodegenerative disease treatment market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Neurodegenerative Disease Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Indication

  • 6.1 Multiple Sclerosis
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Parkinson's Disease
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Alzheimer's Disease
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Spinal Muscular Atrophy (SMA)
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Huntington's Disease
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 N-methyl-D-aspartate Receptor Antagonists
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Selective Serotonin Reuptake Inhibitors
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Dopamine Inhibitors
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectable
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Biogen
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Boehringer Ingelheim International GmbH
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 F. Hoffmann-La Roche AG
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
    • 15.3.4 GlaxoSmithKline Plc
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 SWOT Analysis
    • 15.3.5 Merck & Co. Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Novartis AG
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Pfizer Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Sanofi S.A
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Teva Pharmaceutical Industries Ltd.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 UCB S.A
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Neurodegenerative Disease Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Neurodegenerative Disease Treatment Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Neurodegenerative Disease Treatment Market: Breakup by Indication (in %), 2024
  • Figure 5: Global: Neurodegenerative Disease Treatment Market: Breakup by Drug Type (in %), 2024
  • Figure 6: Global: Neurodegenerative Disease Treatment Market: Breakup by Route of Administration (in %), 2024
  • Figure 7: Global: Neurodegenerative Disease Treatment Market: Breakup by Distribution Channel (in %), 2024
  • Figure 8: Global: Neurodegenerative Disease Treatment Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Neurodegenerative Disease Treatment (Multiple Sclerosis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Neurodegenerative Disease Treatment (Multiple Sclerosis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Neurodegenerative Disease Treatment (Parkinson's Disease) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Neurodegenerative Disease Treatment (Parkinson's Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Neurodegenerative Disease Treatment (Alzheimer's Disease) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Neurodegenerative Disease Treatment (Alzheimer's Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Neurodegenerative Disease Treatment (Spinal Muscular Atrophy- SMA) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Neurodegenerative Disease Treatment (Spinal Muscular Atrophy- SMA) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Neurodegenerative Disease Treatment (Huntington's Disease) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Neurodegenerative Disease Treatment (Huntington's Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Neurodegenerative Disease Treatment (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Neurodegenerative Disease Treatment (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Neurodegenerative Disease Treatment (N-methyl-D-aspartate Receptor Antagonists) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Neurodegenerative Disease Treatment (N-methyl-D-aspartate Receptor Antagonists) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Neurodegenerative Disease Treatment (Selective Serotonin Reuptake Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Neurodegenerative Disease Treatment (Selective Serotonin Reuptake Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Neurodegenerative Disease Treatment (Dopamine Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Neurodegenerative Disease Treatment (Dopamine Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Neurodegenerative Disease Treatment (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Neurodegenerative Disease Treatment (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Neurodegenerative Disease Treatment (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Neurodegenerative Disease Treatment (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Neurodegenerative Disease Treatment (Injectable) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Neurodegenerative Disease Treatment (Injectable) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Neurodegenerative Disease Treatment (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Neurodegenerative Disease Treatment (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Neurodegenerative Disease Treatment (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Neurodegenerative Disease Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Neurodegenerative Disease Treatment (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Neurodegenerative Disease Treatment (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Neurodegenerative Disease Treatment (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Neurodegenerative Disease Treatment (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: North America: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: North America: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: United States: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: United States: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Canada: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Canada: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Asia-Pacific: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Asia-Pacific: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: China: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: China: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Japan: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Japan: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: India: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: India: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: South Korea: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: South Korea: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Australia: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Australia: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Indonesia: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Indonesia: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Others: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Others: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Europe: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Europe: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Germany: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Germany: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: France: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: France: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: United Kingdom: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: United Kingdom: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Italy: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Italy: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Spain: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Spain: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Russia: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Russia: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Others: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Others: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Latin America: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Latin America: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Brazil: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Brazil: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Mexico: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Mexico: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Others: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Others: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Middle East and Africa: Neurodegenerative Disease Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Middle East and Africa: Neurodegenerative Disease Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Middle East and Africa: Neurodegenerative Disease Treatment Market: Breakup by Country (in %), 2024
  • Figure 90: Global: Neurodegenerative Disease Treatment Industry: SWOT Analysis
  • Figure 91: Global: Neurodegenerative Disease Treatment Industry: Value Chain Analysis
  • Figure 92: Global: Neurodegenerative Disease Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Neurodegenerative Disease Treatment Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Neurodegenerative Disease Treatment Market Forecast: Breakup by Indication (in Million USD), 2025-2033
  • Table 3: Global: Neurodegenerative Disease Treatment Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 4: Global: Neurodegenerative Disease Treatment Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 5: Global: Neurodegenerative Disease Treatment Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 6: Global: Neurodegenerative Disease Treatment Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Neurodegenerative Disease Treatment Market: Competitive Structure
  • Table 8: Global: Neurodegenerative Disease Treatment Market: Key Players